# Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)

> **NCT03868969** · PHASE2 · UNKNOWN · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 25 (estimated)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** Fosfomycin Oral Suspension

## Key facts

- **NCT ID:** NCT03868969
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04
- **Primary completion:** 2021-04
- **Final completion:** 2021-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868969, "Clinical Efficacy of Fosfomycin Trometamol Per os in the Treatment of Documented Male Urinary Tract Infections With ESBL-producing Enterobacteriaceae With ESBL Producing Enterobacteriaceae and Resistance Associated With Fluoroquinolones and Cotrimoxazole (FOSF'HOM)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03868969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*